BERKELEY, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. ( ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2019.
Cash, cash equivalents and short term and long term marketable securities totaled $235.4 million at September 30, 2019, compared to $277.9 million at December 31, 2018.
“We remain highly focused on the development of our STING and APRIL programs, with the initiation of our Phase 2 study of ADU-S100 in combination with pembrolizumab in head and neck squamous cell carcinoma and continued progress of our Phase 1 study of BION-1301 in IgA nephropathy,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “Our strong cash position of $235.4 million at the end of the third quarter enables us to continue investing in our STING and APRIL programs with the ultimate goal of providing therapeutic benefit to patients.”
Recent Highlights
- Cleared four healthy volunteer dose cohorts in the single ascending dose portion and one healthy volunteer dose cohort in the multiple ascending dose portion of the Phase 1 clinical trial of BION-1301 for the treatment of IgA nephropathy.
- First patient dosed in Phase 2 clinical trial of ADU-S100 (MIW815) in combination with Keytruda® (pembrolizumab), an approved anti-PD-1 antibody, as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.
Financial Results
- Revenue – Revenue was $4.8 million for the third quarter of 2019 and $13.6 million for the nine months ended September 30, 2019, compared to $3.1 million and $12.3 million, respectively, for the same periods in 2018. The increase in revenue for the quarter and the year to date was primarily due to ratable recognition of the upfront payment received from Eli Lilly in the first quarter of 2019.
- Expenses –
- Research and development expenses were $15.5 million for the third quarter of 2019 and $51.9 million for the nine months ended September 30, 2019, compared to $18.7 million and $58.2 million, respectively, for the same periods in 2018. The quarter and year to date costs decreased primarily due our strategic reset in January 2019, which resulted in reduced headcount and stock-based compensation expense. The reset also resulted in reduced spending towards deprioritized programs partially offset by higher spending towards our STING and APRIL programs.
- General and administrative expenses were $8.7 million for the third quarter of 2019 and $25.8 million for the nine months ended September 30, 2019, compared to $9.1 million and $27.0 million, respectively, for the same periods in 2018. The quarter and year to date costs decreased primarily due to our strategic reset in January 2019, which resulted in reduced headcount and stock-based compensation expense.
- Loss on impairment of intangible assets was $5.0 million for the third quarter of 2019. This expense was recorded due to the discontinuation of one of our acquired early research programs.
- Research and development expenses were $15.5 million for the third quarter of 2019 and $51.9 million for the nine months ended September 30, 2019, compared to $18.7 million and $58.2 million, respectively, for the same periods in 2018. The quarter and year to date costs decreased primarily due our strategic reset in January 2019, which resulted in reduced headcount and stock-based compensation expense. The reset also resulted in reduced spending towards deprioritized programs partially offset by higher spending towards our STING and APRIL programs.
- Net Loss – Net loss for the third quarter of 2019 was $21.0 million or $0.26 per share and $63.0 million or $0.79 per share for the nine months ended September 30, 2019, compared to net loss of $23.1 million or $0.29 per share and $69.0 million or $0.88 per share, respectively, for the same periods in 2018.
About Aduro
Aduro Biotech, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies that are designed to harness the body’s natural immune system for the treatment of patients with challenging diseases. Aduro’s product candidates in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways are being investigated in cancer, autoimmune and inflammatory diseases. ADU-S100 (MIW815), which potentially activates the intracellular STING receptor for a potent tumor-specific immune response, is being evaluated in patients with cutaneously accessible metastatic solid tumors or lymphomas. BION-1301, a first-in-class humanized IgG4 monoclonal antibody that fully blocks APRIL binding to both the BCMA and TACI receptors, is being evaluated in IgA nephropathy. Aduro is collaborating with a number of leading global pharmaceutical companies to help expand and drive its product pipeline. For more information, please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our current intentions or expectations concerning, among other things, the potential for our technology, continued advancement of our programs, continued investment in our lead assets and collaborations with leading global pharmaceutical companies to help expand and drive our product pipeline. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in greater detail under the heading “Risk Factors” contained in our quarterly report on Form 10-Q for the quarter ended September 30, 2019, to be filed with the Securities and Exchange Commission (SEC), and our other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
ADURO BIOTECH, INC.
Consolidated Statements of Operations
(In thousands, except share and per share amounts)
(Unaudited)
| ThreeMonthsEndedSeptember 30, | NineMonthsEndedSeptember30, | ||||||||||||||
| 2019 | 2018 | 2019 | 2018 | ||||||||||||
| Revenue: | |||||||||||||||
| Collaboration and license revenue | $ | 4,799 | $ | 3,063 | $ | 13,625 | $ | 12,329 | |||||||
| Total revenue | 4,799 | 3,063 | 13,625 | 12,329 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 15,510 | 18,675 | 51,916 | 58,223 | |||||||||||
| General and administrative | 8,683 | 9,149 | 25,845 | 27,021 | |||||||||||
| Loss on impairment of intangible assets | 5,006 | — | 5,006 | — | |||||||||||
| Amortization of intangible assets | 138 | 144 | 417 | 443 | |||||||||||
| Total operating expenses | 29,337 | 27,968 | 83,184 | 85,687 | |||||||||||
| Loss from operations | (24,538 | ) | (24,905 | ) | (69,559 | ) | (73,358 | ) | |||||||
| Interest income | 1,366 | 1,353 | 4,334 | 3,892 | |||||||||||
| Other (loss) income, net | (32 | ) | 21 | (54 | ) | (15 | ) | ||||||||
| Loss before income tax | (23,204 | ) | (23,531 | ) | (65,279 | ) | (69,481 | ) | |||||||
| Income tax benefit | 2,252 | 385 | 2,322 | 444 | |||||||||||
| Net loss | $ | (20,952 | ) | $ | (23,146 | ) | $ | (62,957 | ) | $ | (69,037 | ) | |||
| Net loss per common share, basic and diluted | $ | (0.26 | ) | $ | (0.29 | ) | $ | (0.79 | ) | $ | (0.88 | ) | |||
| Shares used in computing net loss per common share, basic and diluted | 80,232,739 | 79,086,841 | 79,940,155 | 78,607,180 | |||||||||||
ADURO BIOTECH, INC.
Consolidated Balance Sheets
(In thousands)
(Unaudited)
| September 30, | December 31, | |||||||
| 2019 | 2018 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 53,605 | $ | 126,310 | ||||
| Short-term marketable securities | 178,182 | 140,129 | ||||||
| Accounts receivable | 222 | 12,037 | ||||||
| Prepaid expenses and other current assets | 3,805 | 4,500 | ||||||
| Total current assets | 235,814 | 282,976 | ||||||
| Long-term marketable securities | 3,593 | 11,434 | ||||||
| Property and equipment, net | 25,534 | 29,157 | ||||||
| Operating lease right-of-use assets | 21,346 | — | ||||||
| Goodwill | 7,949 | 8,334 | ||||||
| Intangible assets, net | 18,608 | 25,135 | ||||||
| Restricted cash | 468 | 468 | ||||||
| Total assets | $ | 313,312 | $ | 357,504 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,643 | $ | 1,457 | ||||
| Accrued clinical trial and manufacturing expenses | 4,012 | 2,542 | ||||||
| Accrued expenses and other liabilities | 9,125 | 10,518 | ||||||
| Operating lease liabilities | 1,700 | — | ||||||
| Deferred revenue | 16,000 | 16,000 | ||||||
| Total current liabilities | 32,480 | 30,517 | ||||||
| Deferred rent | — | 11,063 | ||||||
| Contingent consideration | 975 | 998 | ||||||
| Deferred revenue | 161,203 | 172,671 | ||||||
| Deferred tax liabilities | 3,522 | 6,104 | ||||||
| Operating lease liabilities | 32,120 | — | ||||||
| Other long-term liabilities | 966 | 840 | ||||||
| Total liabilities | 231,266 | 222,193 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 8 | 8 | ||||||
| Additional paid-in capital | 549,705 | 538,895 | ||||||
| Accumulated other comprehensive (loss) income | (178 | ) | 940 | |||||
| Accumulated deficit | (467,489 | ) | (404,532 | ) | ||||
| Total stockholders’ equity | 82,046 | 135,311 | ||||||
| Total liabilities and stockholders’ equity | $ | 313,312 | $ | 357,504 | ||||
Contact:
Noopur Liffick
510-809-2465
[email protected]
[email protected]
